BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

445 related articles for article (PubMed ID: 25104771)

  • 1. Mogamulizumab, an anti-CCR4 antibody, targets human T-lymphotropic virus type 1-infected CD8+ and CD4+ T cells to treat associated myelopathy.
    Yamauchi J; Coler-Reilly A; Sato T; Araya N; Yagishita N; Ando H; Kunitomo Y; Takahashi K; Tanaka Y; Shibagaki Y; Nishioka K; Nakajima T; Hasegawa Y; Utsunomiya A; Kimura K; Yamano Y
    J Infect Dis; 2015 Jan; 211(2):238-48. PubMed ID: 25104771
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mogamulizumab (Anti-CCR4) in HTLV-1-Associated Myelopathy.
    Sato T; Coler-Reilly ALG; Yagishita N; Araya N; Inoue E; Furuta R; Watanabe T; Uchimaru K; Matsuoka M; Matsumoto N; Hasegawa Y; Yamano Y
    N Engl J Med; 2018 Feb; 378(6):529-538. PubMed ID: 29414279
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Demonstration of human T lymphotropic virus type I (HTLV-I) tax-specific CD8+ lymphocytes directly in peripheral blood of HTLV-I-associated myelopathy/tropical spastic paraparesis patients by intracellular cytokine detection.
    Kubota R; Kawanishi T; Matsubara H; Manns A; Jacobson S
    J Immunol; 1998 Jul; 161(1):482-8. PubMed ID: 9647259
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased HTLV type 1 tax specific CD8+ cells in HTLV type 1-asociated myelopathy/tropical spastic paraparesis: correlation with HTLV type 1 proviral load.
    Kubota R; Nagai M; Kawanishi T; Osame M; Jacobson S
    AIDS Res Hum Retroviruses; 2000 Nov; 16(16):1705-9. PubMed ID: 11080814
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tropical spastic paraparesis and HTLV-1 associated myelopathy: clinical, epidemiological, virological and therapeutic aspects.
    Gessain A; Mahieux R
    Rev Neurol (Paris); 2012 Mar; 168(3):257-69. PubMed ID: 22405461
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HTLV-1 induces a Th1-like state in CD4+CCR4+ T cells.
    Araya N; Sato T; Ando H; Tomaru U; Yoshida M; Coler-Reilly A; Yagishita N; Yamauchi J; Hasegawa A; Kannagi M; Hasegawa Y; Takahashi K; Kunitomo Y; Tanaka Y; Nakajima T; Nishioka K; Utsunomiya A; Jacobson S; Yamano Y
    J Clin Invest; 2014 Aug; 124(8):3431-42. PubMed ID: 24960164
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IFN-gamma production in response to Tax 161-233, and frequency of CD4+ Foxp3+ and Lin HLA-DRhigh CD123+ cells, discriminate HAM/TSP patients from asymptomatic HTLV-1-carriers in a Peruvian population.
    Best I; López G; Verdonck K; González E; Tipismana M; Gotuzzo E; Vanham G; Clark D
    Immunology; 2009 Sep; 128(1 Suppl):e777-86. PubMed ID: 19740339
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Flow cytometry evaluation of the T-cell receptor Vbeta repertoire among human T-cell lymphotropic virus type-1 (HTLV-1) infected individuals: effect of interferon alpha therapy in HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP).
    Saito M; Nose H; Usuku K; Sabouri AH; Matsuzaki T; Izumo S; Arimura K; Osame M
    J Neurol Sci; 2006 Jul; 246(1-2):37-43. PubMed ID: 16545396
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term safety and efficacy of mogamulizumab (anti-CCR4) for treating virus-associated myelopathy.
    Sato T; Yamauchi J; Yagishita N; Araya N; Takao N; Ohta Y; Inoue E; Takahashi M; Yamagishi M; Suzuki Y; Uchimaru K; Matsumoto N; Hasegawa Y; Yamano Y
    Brain; 2023 Aug; 146(8):3181-3191. PubMed ID: 37093965
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The elevated interferon gamma production is an important immunological marker in HAM/TSP pathogenesis.
    Montanheiro PA; Penalva de Oliveira AC; Smid J; Fukumori LM; Olah I; da S Duarte AJ; Casseb J
    Scand J Immunol; 2009 Oct; 70(4):403-7. PubMed ID: 19751276
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HTLV-I specific IFN-gamma+ CD8+ lymphocytes correlate with the proviral load in peripheral blood of infected individuals.
    Kubota R; Kawanishi T; Matsubara H; Manns A; Jacobson S
    J Neuroimmunol; 2000 Jan; 102(2):208-15. PubMed ID: 10636490
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Immunopathogenesis and treatment of the myelopathy associated to the HTLV-I virus].
    Carod-Artal FJ
    Rev Neurol; 2009 Feb 1-15; 48(3):147-55. PubMed ID: 19206063
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human T cell leukemia virus Type I (HTLV-I) infection induces greater expansions of CD8 T lymphocytes in persons with HTLV-I-associated myelopathy/tropical spastic paraparesis than in asymptomatic carriers.
    Ureta-Vidal A; Pique C; Garcia Z; Dehée A; Tortevoye P; Désiré N; Gessain A; Chancerel B; Gout O; Lemonnier FA; Cochet M
    J Infect Dis; 2001 Mar; 183(6):857-64. PubMed ID: 11237801
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human T-lymphotropic virus 1 (HTLV-1)-associated lichenoid dermatitis induced by CD8+ T cells in HTLV-1 carrier, HTLV-1-associated myelopathy/tropical spastic paraparesis and adult T-cell leukemia/lymphoma.
    Tokura Y; Ito T; Kawakami C; Sugita K; Kasuya A; Tatsuno K; Sawada Y; Nakamura M; Shimauchi T
    J Dermatol; 2015 Oct; 42(10):967-74. PubMed ID: 26077665
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Presence of tropical spastic paraparesis/human T-cell lymphotropic virus type 1-associated myelopathy (TSP/HAM)-like among HIV-1-infected patients.
    Casseb J; de Oliveira AC; Vergara MP; Montanheiro P; Bonasser F; Meilman Ferreira C; Smid J; Duarte AJ
    J Med Virol; 2008 Mar; 80(3):392-8. PubMed ID: 18205234
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical trial of a humanized anti-IL-2/IL-15 receptor β chain in HAM/TSP.
    Enose-Akahata Y; Oh U; Ohayon J; Billioux BJ; Massoud R; Bryant BR; Vellucci A; Ngouth N; Cortese I; Waldmann TA; Jacobson S
    Ann Clin Transl Neurol; 2019 Aug; 6(8):1383-1394. PubMed ID: 31402625
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exacerbated inflammatory cellular immune response characteristics of HAM/TSP is observed in a large proportion of HTLV-I asymptomatic carriers.
    Santos SB; Porto AF; Muniz AL; de Jesus AR; Magalhães E; Melo A; Dutra WO; Gollob KJ; Carvalho EM
    BMC Infect Dis; 2004 Mar; 4():7. PubMed ID: 15070424
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HTLV-I-associated myelopathy/tropical spastic paraparesis (HAM/TSP): the role of HTLV-I-infected Th1 cells in the pathogenesis, and therapeutic strategy.
    Nakamura T
    Folia Neuropathol; 2009; 47(2):182-94. PubMed ID: 19618340
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) inflammatory network.
    Goncalves DU; Proietti FA; Barbosa-Stancioli EF; Martins ML; Ribas JG; Martins-Filho OA; Teixeira-Carvalho A; Peruhype-Magalhães V; Carneiro-Proietti AB
    Inflamm Allergy Drug Targets; 2008 Jun; 7(2):98-107. PubMed ID: 18691139
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduction in HTLV-I proviral load and spontaneous lymphoproliferation in HTLV-I-associated myelopathy/tropical spastic paraparesis patients treated with humanized anti-Tac.
    Lehky TJ; Levin MC; Kubota R; Bamford RN; Flerlage AN; Soldan SS; Leist TP; Xavier A; White JD; Brown M; Fleisher TA; Top LE; Light S; McFarland HF; Waldmann TA; Jacobson S
    Ann Neurol; 1998 Dec; 44(6):942-7. PubMed ID: 9851439
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.